Goals of MS Therapy

" When a person has multiple grow it is impossible to predict the course of the disease that individual. But there are some general trend. And at some point people within this will likely experience relapses. And -- experience problems with cognition or walking. Your -- one of the neat things that's most important to have -- their ability to detect and Hillary to get around at home work play. -- and multiples or are frequently attacked her ability to walk. Untreated large studies have shown that most people would MF would Syrians some problems walking we didn't -- to diagnose."

" about ten years. After -- and that's the probably noticed they're having some difficulties and gate it may be difficulties. And actually walking or walking the same -- advocate higher the disease. Then -- there he's goes on ten to eighteen years. It probably would need on the device at least one cited a device like McCain are cracks to help them get around. Probably twenty years. Or maybe a little bit longer where they would actually need -- like a wheelchair or bilateral. Meeting. To -- approaches to get around."

" Study also shows that many people with and that was experienced problems in healthy thing especially without treatment. Cognitive technical. Difficulty with memory. Difficulty with problems are difficult to multitasking."

" Occur frequently written -- and a out at 8% of people. And -- eighteen years in of their home will be aware that they slowed down hard heavily in some way."

" Within the last eighteen years researchers have developed a series of what are called the east -- line drugs. There have been shown to alter the course of and then various clinical trials you clear benefit. Including studies with drugs known as interferon."

" That they -- and I'm data has shown us that we can decrease the progression of accumulated disability in two years. With both of the interferon beta one product. Abbott and Rita have decreased. The rate of decline accumulated physical disability two years by about 37%. Revamp the with a higher dose showed that about 30%. Measuring decreases in physical line can be subjected to."

" Designers of the -- use benchmark on which doctors and they're in an easily agree."

" We measure. That time problem to a patient progress in a unit of disability were both -- and."

" And doctor clearly recognized that you know what I'm worst."

" And when we apply about scale recognize and there are all on patients could be at a different point in the pack of impairment. -- we can't make sure that and that individual patient who received error. At that time to program under a point where they would go to their position but noted they were worse hasn't been one. And to what extent does that wind and wind and about thirty to 40%. Compared to him it."

" Is that gathered evidence do that at least sound of the disease modifying drugs and delete cognitive problems in an --"

" What's happening in -- Iran out. -- put people through and -- psychological battery of tests. And another carpet at which is -- to task. And we sobbed benefit in terms of duration on a -- with both of the product and I got more robust -- that autumn both. We didn't you that would be bad or a --"

" That goes quite well with the ability of these drugs to slow physical impairment are. I think it's not her real reason. Why beginning -- treatment early is important. When you've lost cognition. -- lost the ability to walk in virtually impossible to get back. Yet another minister of the active disease modifying drugs."

" Is it decreased in the frequency and relapse. We are happy right now I'm great deal of Abbott at bat Peter job. And compact did not -- disease activity but let's take you individually. We do now back -- Tehran and reduce exacerbate should write a number of attacks again and 12 or three years. By about thirty per cent. And that and challenge and not ones and not to study -- four separate. Are they three clinical trials -- later Tehran's -- attack frequency by 32%. In one trial -- exacerbation were all -- decreased by about thirty per. So are therapies and really -- fine this measure. And that's disease activity. You rate at which you experience attack."

" Just a few years ago there was little rushed to diagnose multiples -- because they wouldn't know most active drugs to slow the east. Now did you clear trend -- early diagnosis. And therapy can begin as soon as possible. -- a little cure during therapy it will likely low -- and down in very significant way these drugs are not used to stop."

" Progression. And -- or to undo what's been done -- and two people doing better prolonged period of time and -- are functioning level -- longer period of time I like to tell my patients with -- or that the disease can be treated them like. In -- one per and I can't predict that the future will be. But untreated multiple camera -- in the majority. And does result in impairment. And that's something we have buoyed by early as -- and treatment."